Recruiting

Stopping blood cancer treatment after remission is achieved

Plain-English translation of NCT06557421 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether patients with acute myeloid leukemia (a blood cancer) can safely stop taking and after their cancer goes into remission. Right now, patients typically stay on this medication for a long time. The study wants to see if stopping the medication is safe and whether patients stay cancer-free with careful monitoring instead of staying on treatment indefinitely.

Long-term cancer medications can cause side effects and affect quality of life. This trial investigates whether patients who have already achieved remission actually need to keep taking the medication, or whether regular monitoring alone is enough to keep the cancer under control.

Do you qualify?

You likely qualify if…

you are 18 years of age or older
you have been newly diagnosed with acute myeloid leukemia
you have received venetoclax and azacitidine as your first treatment for at least 12 months
your cancer is in complete remission (meaning no detectable cancer cells or very low levels)
you have no signs of minimal residual disease (tiny amounts of remaining cancer cells cannot be detected in your blood or bone marrow)
you are able to attend regular follow-up appointments and comply with the study schedule

You likely don't qualify if…

you received venetoclax and azacitidine as a salvage therapy (rescue treatment after a prior treatment failed)
you have previously had an allogeneic stem cell transplant
your cancer stopped responding to the medication or you lost your remission
you have a serious medical or mental health condition that would prevent you from completing the follow-up monitoring

What participation looks like

You will stop taking the medication after about 12 months of treatment and enter a monitoring phase. You will have regular check-ups where your doctors will test your blood and bone marrow to watch for any signs that the cancer is returning. Your participation will involve repeated visits for blood draws and possibly bone marrow tests over an extended period to make sure you stay cancer-free.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(1 site)

France

Institut Paoli-Calmettes, Marseille